Výsledky vyhledávání - "Maria Ardaiz"

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Publikováno v: Blood. 138:3486-3486

Background: Genetic information has become critical to understand the development of T-cell acute lymphoblastic leukemia (T-ALL) and to elucidate the origin of disease relapse. Several genetic markers, together with measurable residual disease (MRD),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d63dd51c987efd68e1ebbacc3a79d9d
https://doi.org/10.1182/blood-2021-148263

Zobrazit plný text záznamu

90y-Ibritumomab Tiuxetan Treatment for Relapsed and/or Refractory B-Cell Non- Hodgkin’S Lymphoma. Multi-Institutional Argentinian Study. An Update

Publikováno v: Blood. 112:5009-5009

Background: 90Y-ibritumomab tiuxetan (Zevamab®; ZEV; Bayer-Schering Pharma- Argentina) has been approved for the treatment of relapsed, refractory and transformed (high grade) follicular lymphomas. Methods: Between Sep. 2005 and Feb. 2008, 45 patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a4f041f3f3e57eb1001286dca6bd25d
https://doi.org/10.1182/blood.v112.11.5009.5009

Zobrazit plný text záznamu

90Y-Ibritumomab Treatment for Relapsed and/or Refractory B Cell Type Non-Hodgkin’s Lymphoma. Multiinstitutional Argentinian Study

Publikováno v: Blood. 110:4484-4484

The radionucleid conjugate with monoclonal antibodies (antiCD20/90Y-ibritumomab tiuxetan) have been approved for the treatment of relapsed, refractory and transformed (high grade) follicular lymphomas. Between September 2005 and August 2007, 41 patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ceaac25a5366ca17a75d9f831d389a47
https://doi.org/10.1182/blood.v110.11.4484.4484

Zobrazit plný text záznamu

A Phase 2 Study of 90Y-Ibritumomab Tiuxetan (90Y-Zevalin®) in Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preliminary Report of the Argentinean Cooperative Group

Autor: Jorge Milone, Dardo Riveros, Maria Cecilia Foncuberta, Pedro Negri, Juan Dupont, Leandro Riera, Javier Bordone, Maria Ardaiz, Fernando Bezares, Gustavo Milone, Roberto Cacchione

Publikováno v: Blood. 108:4688-4688

Background. In our experience, in Argentina, the use of rituximab + chemotherapy in relapsed/refractory CD20+ follicular (FL) non-Hodgkin’s lymphoma results in Methods. Between September 2005 and November 2005, we recruited 10 patients (pts; 6 male

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b07f88e66dc9d8bc7102ab0c2716745
https://doi.org/10.1182/blood.v108.11.4688.4688

Zobrazit plný text záznamu

Rituximab - Inmunotherapy Combined with Chemotherapy, CHOP for the Treatment of Patients with Difusse Large B - Cell Lymphoma (DLBCL)

Autor: Ider Cerutti, Carlos Cánepa, Jorge Milone, Alfredo Basso, Dardo Riveros, Marta Zerga, Fernando Bezares, Gustavo Kusminsky, Maria Ardaiz, Luis Palmer, Marta Gelemur

Publikováno v: Blood. 106:4745-4745

Several studies (GELA 98.5, MInT) have demonstrated the benefit of combination rituximab (R) with chemotherapy to improve event free and overall survival in patients with DLBCL. We analyzed retrospectively the safety of combination R-CHOP for 6 cycle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59b63227fab42693c9553d22e0affd19
https://doi.org/10.1182/blood.v106.11.4745.4745

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání